ALVAC(2)120(B,MN)GNP (vCP1452)
Sponsors
National Institute of Allergy and Infectious Diseases (NIAID)
Conditions
HIV InfectionsHIV Seronegativity
Phase 1
A Study of the Effects of Giving Two Anti-HIV Vaccines to Babies of HIV-Positive Mothers
CompletedNCT00000879
End: 2005-04-30Target: 48Updated: 2021-10-29
A Study of the Safety and Effectiveness of an HIV Vaccine for HIV-Positive Patients Receiving Anti-HIV Drugs for at Least 2 Years
CompletedNCT00006509
End: 2007-06-30Target: 12Updated: 2015-03-09
Immune Responses in HIV-Positive Patients Receiving an Anti-HIV Drug Combination When Given the HIV Vaccines Remune and vCP1452
CompletedNCT00006495
End: 2004-09-30Target: 80Updated: 2021-11-01
Vaccine (ALVAC-HIV vCP1452) Use and Intermittent Withdrawal of Anti-HIV Drugs in Patients With HIV
CompletedNCT00011011
Start: 2001-02-28End: 2006-10-31Updated: 2021-11-01
Safety and Effectiveness of Anti-HIV Vaccines in HIV-Negative Adults
CompletedNCT00000904
End: 1999-08-31Target: 100Updated: 2021-11-04
Safety/Immunogenicity of Immunizations of ALVAC-DC-SC vs ALVAC-SC
CompletedNCT00026624
End: 2006-10-31Updated: 2021-11-01
Safety and Immune Response Study of High-Dose Canarypox ALVAC-HIV Vaccine in Healthy, HIV Uninfected Adults
CompletedNCT00027261
End: 2005-12-31Updated: 2021-10-14
Phase 2
Immune Therapies and Anti-HIV Therapy Withdrawal in Controlling Viral Load
CompletedNCT00013663
End: 2006-06-30Target: 92Updated: 2012-11-02
Safety and Immune Response Study of the Vaccine ALVAC vCP1452 Alone or in Combination With AIDSVAX B/B
CompletedNCT00007332
End: 2003-04-30Target: 330Updated: 2021-10-15
ALVAC-HIV vCP1452 Alone and Combined With MN rgp120
CompletedNCT00011037
End: 2004-07-31Updated: 2021-10-14
Safety and Effectiveness of Adding Either an HIV Vaccine, Interleukin-2, or Both to a Patient's Anti-HIV Drug Combination
CompletedNCT00006291
End: 2005-10-31Target: 100Updated: 2021-11-01